| Status |
Official Title |
Lead Investigator |
Last Updated |
| Finalised |
Post-authorisation safety study in patients with type 2 diabetes mellitus to assess the risk of acute liver injury, acute kidney injury and chronic kidney disease, severe complications of urinary tract infection, genital infections, and diabetic ketoacidosis among patients treated with empagliflozin compared to patients treated with DPP-4 inhibitors |
Dr Cristina Rebordosa |
06/11/2023 |
| Finalised |
An observational cohort study to describe intermittent OCS utilisation and its association with adverse outcomes and healthcare resource use and costs in asthma using the OPCRD and CPRD databases. |
Professor David Price |
31/08/2023 |
| Finalised |
Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids |
Dr Jordi Castellsague |
24/03/2022 |
| Finalised |
 Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids |
Dr Alejandro Arana |
24/03/2022 |
| Finalised |
WWE117397: Post-authorization safety Electronic Medical Records database retrospective cohort study of new users of inhaled UMEC/VI or new users of inhaled UMEC in the primary care setting: UK EMR distributed network study |
Mr Daniel Dedman |
17/05/2021 |
| Finalised |
Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee |
Mr Robert Flynn |
20/02/2020 |
| Finalised |
Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands, Spain, United Kingdom and Finland |
Dr Ron Herings |
02/05/2019 |
| Finalised |
A drug utilisation study of Rifaxamin-α 550mg |
Ms Jennifer Campbell |
28/02/2019 |
| Finalised |
Evaluation of potential off-label use of dabigatran etexilate in Europe |
Dr Manel Pladevall-Vila |
20/09/2018 |
| Finalised |
Pan European Multi-Database Bladder Cancer Risk Characterisation Study |
Dr Pasi Korhonen |
30/05/2017 |
| Ongoing |
DARWIN EU® CC - Rates of occurrence of treatment-related intercurrent events in patients with major depressive disorder |
Mr Johnmary Arinze |
13/11/2023 |
| Ongoing |
FINErenone druG Utilization Study and assessment of Temporal changes following availability of different treatment options in patients with chronic kidney disease and type 2 diabetes |
Dr Catherine Johannes |
15/06/2023 |
| Ongoing |
Methods for controlling by indication for prescriptions: application to medications for neuropathic pain |
Dr Christine Damase-Michel |
04/10/2021 |
| Ongoing |
VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006) |
Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. |
29/10/2020 |
| Ongoing |
EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE |
Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. |
29/10/2020 |
| Ongoing |
EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE |
Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. |
29/10/2020 |
| Ongoing |
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance |
Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. |
29/10/2020 |
| Ongoing |
Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs |
Ms Tarita Murray-Thomas |
19/05/2017 |
| Planned |
Utilization of antidementia treatments: a large multinational-network population-based study. |
Dr Carlen Reyes |
04/04/2023 |
| Planned |
Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to medication for migraine in pregnancy |
Professor Hedvig Nordeng |
04/10/2021 |
